Valsartan has been evaluated in numerous clinical trials across all phases of development, targeting conditions such as hypertension, heart failure with reduced ejection fraction, acute ischemic stroke, type 2 diabetes, and proteinuria. Sponsored by both pharmaceutical companies and academic institutions, these studies feature diverse recruitment statuses, including completed, actively recruiting, and withdrawn. Overall, this research profile highlights the extensive therapeutic investigation of valsartan across various cardiovascular and metabolic pathologies.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06930885 | RECRUITING | Atherothrombotic Diseases; Atherosclerotic Cardiovascular Disease (ASCVD) |
Hospital do Coracao |
2025-06-12 | PHASE3 |
| NCT03686657 | WITHDRAWN | Type 2 Diabetes; High Blood Pressure; Arthritis; Obesity |
ARKAY Therapeutics |
2026-12-10 | PHASE1; PHASE2 |
| NCT05155137 | RECRUITING | Stroke; Cognitive Decline |
Hospital Moinhos de Vento |
2021-12-20 | PHASE3 |
| NCT07458880 | RECRUITING | Intracerebral Hemorrhage |
The University of Hong Kong |
2026-03-01 | |
| NCT07539298 | RECRUITING | Atrial Functional Mitral Regurgitation |
Jonathan Beaudoin |
2026-07-13 | PHASE2; PHASE3 |
| NCT05194111 | RECRUITING | Heart Failure; Heart Dysfunction |
Virginia Commonwealth University |
2022-08-11 | PHASE1; PHASE2 |
| NCT06704633 | RECRUITING | Heart Failure |
Martin Rohacek |
2026-06-30 | PHASE4 |
| NCT07491718 | RECRUITING | Takotsubo Cardiomyopathy |
University of Edinburgh |
2025-08-08 | |
| NCT05508035 | RECRUITING | Heart Failure With Moderately Reduced Ejection Fraction |
John Paul II Hospital, Krakow |
2023-07-13 | PHASE3 |
| NCT07572032 | RECRUITING | Heart Failure Due to Coronary Artery Disease; Valvular Cardiomyopathy; Heart Failure |
Kyungsub Song |
2026-05-20 | PHASE4 |
| NCT06863987 | ENROLLING_BY_INVITATION | Essential Hypertension |
Shandong New Time Pharmaceutical Co., LTD |
2025-02-05 | PHASE3 |
| NCT05465031 | RECRUITING | Breast Cancer; Neoplasm, Breast; Breast Diseases; Antihypertensive Agents; Sacubitril/Valsartan; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Molecular Mechanisms of Pharmacological Action; Heart Failure; Cardiac Toxicity; Cancer, Therapy-Related; Cancer Therapy-Related Cardiac Dysfunction; Cardiotoxicity |
Silesian Centre for Heart Diseases |
2024-04-17 | PHASE4 |
| NCT07139405 | NOT_YET_RECRUITING | Type 2 Diabetes (T2DM) |
Myopharm Limited |
2026-09-01 | PHASE2 |
| NCT06053580 | RECRUITING | Pulmonary Arterial Hypertension; Right Heart Failure; Right Ventricular Dysfunction; Pulmonary Vascular Disorder |
University of Washington |
2024-02-28 | PHASE2 |
| NCT06712030 | NOT_YET_RECRUITING | Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) |
Puerta de Hierro University Hospital |
2025-01 | PHASE3 |
| NCT05279742 | ENROLLING_BY_INVITATION | Heart Failure With Preserved Ejection Fraction; Chronic Kidney Diseases |
Horng Chen |
2022-11-04 | PHASE1; PHASE2 |
| NCT04971720 | RECRUITING | Obesity; Cardiovascular Diseases; Hypertension; Nocturnal Blood Pressure; Natriuretic Peptides; Renin-Angiotensin-Aldosterone System |
University of Alabama at Birmingham |
2022-02-18 | PHASE2; PHASE3 |
| NCT04055428 | RECRUITING | Diabetes Mellitus; Cardiovascular Diseases; Insulin Sensitivity/Resistance; Metabolic Disease; Natriuretic Peptides; Metabolism; Energy Expenditure |
University of Alabama at Birmingham |
2020-08-15 | PHASE2 |
| NCT06693674 | RECRUITING | Congenital Heart Disease |
Mayo Clinic |
2025-02-03 | PHASE3 |
| NCT06917664 | RECRUITING | Coronary Artery Disease; Ischemic Mitral Regurgitation; Angiotensin Receptor/Neprilysin Inhibitor |
China National Center for Cardiovascular Diseases |
2025-06-05 | PHASE4 |
| NCT06900803 | NOT_YET_RECRUITING | Heart Failure With Reduced Ejection Fraction (HFrEF); Sacubitril/Valsartan; Medication Adherence |
National Taiwan University Hospital |
2025-04-07 | |
| NCT06536309 | WITHDRAWN | Heart Failure With Preserved Ejection Fraction; Myocardial Fibrosis |
Brigham and Women's Hospital |
2026-08-27 | PHASE4 |
| NCT02966665 | RECRUITING | Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure; Hypertension |
Russell Richardson |
2008-09 | PHASE1 |
| NCT03508739 | SUSPENDED | Diabetes Mellitus, Type 2; Pre-diabetic; Hypertension; Elevated Blood Pressure |
University of Pennsylvania |
2018-06-01 | PHASE3 |
| NCT07417215 | COMPLETED | Heart Failure With Preserved Ejection Fraction (HFPEF); Hemodialysis; Sacubitril/Valsartan |
University Clinical Hospital Mostar |
2026-01-30 | PHASE4 |
| NCT06716970 | NOT_YET_RECRUITING | Essential Hypertension |
Wuhan Createrna Science and Technology Co., Ltd |
2024-12-30 | PHASE3 |
| NCT06035978 | UNKNOWN | Cardiovascular Diseases; Heart Failure With Reduced Ejection Fraction |
University Hospital Ostrava |
2024-03 | PHASE4 |
| NCT07444398 | RECRUITING | Decompensated Heart Failure |
Khawaja Danish Ali |
2026-01-01 | PHASE1 |
| NCT06643819 | RECRUITING | Essential Hypertension |
Chong Kun Dang Pharmaceutical |
2024-10-14 | PHASE3 |
| NCT06771245 | NOT_YET_RECRUITING | Mild-to-moderate Essential Hypertension |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2025-01-24 | PHASE3 |
| NCT07544888 | COMPLETED | Heart Diseases; Hypertension |
Shaikh Zayed Hospital, Lahore |
2025-11-01 | PHASE1 |
| NCT07341893 | COMPLETED | Heart Failure |
Damanhour University |
2025-08-01 | |
| NCT07379788 | COMPLETED | Heart Failure |
Rehab Werida |
2025-01-01 | |
| NCT07192341 | RECRUITING | Sacubitril/Valsartan; Prosthetic Heart Valve; Heart Failure; Reduced Ejection Fraction |
Kafrelsheikh University |
2025-09-27 | |
| NCT05498181 | COMPLETED | Hemodialysis |
Brigham and Women's Hospital |
2022-10-11 | PHASE2 |
| NCT05528419 | COMPLETED | Atrial Fibrillation Recurrent; Hypertension |
Shanghai Jiao Tong University School of Medicine |
2023-02-06 | PHASE4 |
| NCT07331389 | RECRUITING | Overweight Subject; Healthy Subjects |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
2025-09-24 | PHASE1 |
| NCT06218199 | RECRUITING | Heart Failure, Congestive |
Heart Center Research, LLC |
2021-07-08 | PHASE4 |
| NCT05638880 | COMPLETED | Diabetic Nephropathies |
Mostafa Bahaa |
2022-12-20 | PHASE2 |
| NCT04263922 | UNKNOWN | Renal Insufficiency, Chronic |
The First Affiliated Hospital of Dalian Medical University |
2020-06-30 | PHASE4 |
| NCT05991284 | COMPLETED | Heart Failure With Preserved Ejection Fraction; Functional Mitral Regurgitation |
Ziekenhuis Oost-Limburg |
2024-02-29 | PHASE4 |
| NCT06344247 | UNKNOWN | Obesity; Chronic Kidney Diseases |
RenJi Hospital |
2023-09-01 | |
| NCT05989503 | COMPLETED | Heart Failure With Reduced Ejection Fraction |
Universidade do Porto |
2023-08-04 | PHASE4 |
| NCT04153136 | COMPLETED | HIV/AIDS; Heart Failure With Preserved Ejection Fraction |
Massachusetts General Hospital |
2020-09-11 | PHASE2 |
| NCT03315832 | WITHDRAWN | Aortic Valve Stenosis; Valsartan; Angiotensin Receptor Antagonists; Transcatheter Aortic Valve Replacement; Heart Valve Prosthesis Implantation; Hypertrophy, Left Ventricular |
University Hospital, Limoges |
2023-01-02 | PHASE2; PHASE3 |
| NCT03476616 | COMPLETED | Hypertension; Obesity |
Hippocration General Hospital |
2018-09-01 | PHASE4 |
| NCT06501651 | UNKNOWN | Essential Hypertension; Type 2 Diabetes; Nephropathy |
Sichuan Academy of Medical Sciences |
2024-08-01 | PHASE4 |
| NCT05920005 | COMPLETED | Hypertension |
Hospital Israelita Albert Einstein |
2023-08-22 | PHASE3 |
| NCT04023227 | COMPLETED | Chagas Disease; Heart Failure |
Novartis Pharmaceuticals |
2019-12-10 | PHASE4 |
| NCT07023016 | COMPLETED | Acute Decompensated Heart Failure (ADHF); Chronic Kidney Disease (CKD) |
National Heart Institute, Egypt |
2023-11-01 | PHASE2; PHASE3 |
| NCT05487261 | UNKNOWN | Heart Failure |
Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań |
2022-12-13 | PHASE4 |
| NCT04103554 | UNKNOWN | Heart Failure |
University of Zagreb |
2021-02-05 | PHASE4 |
| NCT06922253 | COMPLETED | Chronic Heart Failure |
Humanis Saglık Anonim Sirketi |
2024-12-28 | PHASE1 |
| NCT05593575 | COMPLETED | Diabetic Kidney Disease |
Shanghai Pharmaceuticals Holding Co., Ltd |
2023-03-22 | PHASE2 |
| NCT04853758 | UNKNOWN | Chagas Cardiomyopathy |
University of Sao Paulo General Hospital |
2021-05-06 | PHASE3 |
| NCT07327749 | COMPLETED | Hypertension |
Shiraz University of Medical Sciences |
2022-10-01 | PHASE4 |
| NCT03738878 | TERMINATED | Hypertension |
Vanderbilt University Medical Center |
2018-11-15 | PHASE4 |
| NCT06142383 | TERMINATED | Heart Failure |
Novartis Pharmaceuticals |
2023-12-12 | PHASE2 |
| NCT05269615 | UNKNOWN | Exercise Physiology |
The University of Hong Kong |
2023-03-20 | PHASE4 |
| NCT03760588 | COMPLETED | Breast Cancer Female; Heart Failure |
Torbjorn Omland |
2019-01-31 | PHASE2 |
| NCT06149104 | COMPLETED | Heart Failure |
Novartis Pharmaceuticals |
2023-12-04 | PHASE3 |
| NCT06193044 | UNKNOWN | Healthy Volunteer |
International Bio service |
2024-05-07 | PHASE1 |
| NCT03553810 | COMPLETED | Hypertensive Heart Disease |
National Heart Centre Singapore |
2019-04-12 | PHASE2 |
| NCT06248112 | UNKNOWN | Healthy Subjects |
Bio-innova Co., Ltd |
2024-05-06 | PHASE1 |
| NCT05271448 | UNKNOWN | Contrast-induced Nephropathy; Chronic Kidney Diseases; Ischemic Heart Disease |
An-Najah National University |
2021-06-01 | |
| NCT05095922 | COMPLETED | Diabetes Mellitus, Type 2; Diabetic Angiopathies |
Affiliated Hospital of Nantong University |
2023-03-28 | PHASE4 |
| NCT06273254 | UNKNOWN | Bioequivalence Study |
Viatris Inc. |
2024-04 | PHASE1 |
| NCT06266988 | UNKNOWN | Chronic Heart Failure |
Viatris Inc. |
2024-03 | PHASE1 |
| NCT06357104 | COMPLETED | COVID-19 Vaccine Adverse Reaction |
Pachankis, Yang I., M.D. |
2024-02-26 | PHASE4 |
| NCT06090487 | COMPLETED | Heart Failure |
Ain Shams University |
2024-02-01 | |
| NCT06193187 | UNKNOWN | Healthy Volunteers |
Dr. Reddy's Laboratories (Thailand) Limited |
2024-01 | PHASE1 |
| NCT05164653 | UNKNOWN | Heart Failure |
Saga University |
2021-12-27 | PHASE4 |
| NCT03938389 | ACTIVE_NOT_RECRUITING | PreDiabetes; Impaired Glucose Tolerance; Obesity; Blood Pressure |
Ohio State University |
2020-02-25 | PHASE4 |
| NCT05056727 | TERMINATED | Renal Insufficiency, Chronic; Hyperkalemia |
AstraZeneca |
2021-09-30 | PHASE3 |
| NCT03785405 | COMPLETED | Heart Failure |
Novartis Pharmaceuticals |
2019-05-02 | PHASE3 |
| NCT05359068 | COMPLETED | Essential Hypertension |
Shanghai Pharmaceuticals Holding Co., Ltd |
2021-06-10 | PHASE3 |
| NCT05212597 | UNKNOWN | Aortic Valve Insufficiency |
Samsung Medical Center |
2022-01-12 | PHASE2 |
| NCT06487949 | COMPLETED | Hypertension |
Shiraz University of Medical Sciences |
2022-12-01 | PHASE4 |
| NCT04164732 | COMPLETED | Cardiomyopathy, Hypertrophic |
Novartis Pharmaceuticals |
2020-01-08 | PHASE2 |
| NCT07700875 | COMPLETED | Essential Hypertension |
Wuhan Createrna Science and Technology Co., Ltd |
2022-12-29 | PHASE2 |
| NCT05989503 | Recruiting | Heart Failure With Reduced Ejection Fraction |
Universidade do Porto|Unidade de Investigação e Desenvolvimento Cardiovascular (UnIC)|Rede de Investigação em Saúde |
2023-08-04 | Phase 4 |
| NCT05580510 | UNKNOWN | Congenital Heart Disease; Heart Failure; Heart Failure With Reduced Ejection Fraction |
Instituto Nacional de Cardiologia Ignacio Chavez |
2023-02-06 | PHASE2; PHASE3 |
| NCT03928158 | COMPLETED | Heart Failure; Essential Hypertension |
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation |
2019-05-31 | PHASE2 |
| NCT05881720 | COMPLETED | Heart Failure |
Damanhour University |
2022-01-01 | PHASE4 |
| NCT04883528 | COMPLETED | Covid19 |
Duke University |
2021-08-06 | PHASE1; PHASE2 |
| NCT04637555 | WITHDRAWN | Post Myocardial Infarction |
Novartis Pharmaceuticals |
2021-05-26 | PHASE3 |
| NCT03594825 | UNKNOWN | Hypertension;Nephropathy |
Fifth Affiliated Hospital, Sun Yat-Sen University |
2018-11 | PHASE4 |
| NCT04769778 | UNKNOWN | Chronic Kidney Allograft Nephropathy |
Josep M Cruzado |
2020-02-19 | PHASE4 |
| NCT04929600 | UNKNOWN | Hypertension; Left Ventricular Hypertrophy |
Shanghai Jiao Tong University School of Medicine |
2021-11-28 | PHASE4 |
| NCT05870709 | Withdrawn | Heart Failure |
Novartis Pharmaceuticals|Novartis |
2023-05-15 | -- |
| NCT05681273 | COMPLETED | T2DM |
Chipscreen Biosciences, Ltd. |
2023-02-17 | PHASE1 |
| NCT05117736 | TERMINATED | Systemic Right Ventricle; Heart Failure |
Montreal Heart Institute |
2022-03-15 | |
| NCT05243199 | COMPLETED | CKD5 Stage Dialysis; Heart Failure |
Ruijin Hospital |
2020-08-01 | PHASE4 |
| NCT03988634 | COMPLETED | Heart Failure With Preserved Ejection Fraction (HFpEF) |
Novartis Pharmaceuticals |
2019-06-29 | PHASE3 |
| NCT04572724 | UNKNOWN | Peritoneal Dialysis Complication; Hemodialysis Complication; Heart Failure |
Shenzhen Second People's Hospital |
2020-07-06 | PHASE4 |
| NCT04197050 | UNKNOWN | Myocardial Injury; Connective Tissue Diseases |
RenJi Hospital |
2020-02-20 | PHASE4 |
| NCT05545059 | UNKNOWN | Resistant Hypertension |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2022-09-24 | PHASE3 |
| NCT05060588 | UNKNOWN | Myocardial Infarction; Hypertension |
Qingdao Central Hospital |
2021-10 | PHASE4 |
| NCT05564572 | Enrolling by invitation | Heart Failure |
Stanford University |
2022-09-07 | Not Applicable |
| NCT05194111 | Recruiting | Heart Failure|Heart Dysfunction |
Virginia Commonwealth University |
2022-08-11 | Phase 1|Phase 2 |
| NCT04637152 | COMPLETED | Resistant Hypertension; Blood Pressure |
Hospital Geral Roberto Santos |
2020-11-11 | PHASE2 |
| NCT05053893 | UNKNOWN | Cardio-Renal Syndrome |
The Affiliated Hospital of Qingdao University |
2021-09-22 | |
| NCT03893435 | COMPLETED | Acute Myocardial Infarction |
The Young Investigator Group of Cardiovascular Research |
2018-12-01 | |
| NCT04587947 | COMPLETED | Heart Failure Patients |
St. Josefs-Hospital Wiesbaden GmbH |
2020-04-01 | |
| NCT02884206 | COMPLETED | Chronic Heart Failure (CHF) |
Novartis Pharmaceuticals |
2016-11-23 | PHASE3 |
| NCT03832660 | COMPLETED | Hypertrophic Cardiomyopathy |
Newcastle University |
2019-05-03 | PHASE2 |
| NCT03553303 | UNKNOWN | Heart Failure, Systolic |
Oslo University Hospital |
2018-10-16 | PHASE4 |
| NCT04606563 | TERMINATED | Covid19; SARS-CoV Infection |
University of British Columbia |
2020-10-09 | PHASE3 |
| NCT03300427 | COMPLETED | Heart Failure |
Novartis Pharmaceuticals |
2018-07-05 | PHASE4 |
| NCT04912167 | UNKNOWN | STEMI |
West China Hospital |
2021-11 | PHASE3 |
| NCT04191681 | RECRUITING | Stage D Heart Failure |
The Cleveland Clinic |
2019-11-08 | PHASE4 |
| NCT05366101 | COMPLETED | Hypertrophic Cardiomyopathy |
Newcastle-upon-Tyne Hospitals NHS Trust |
2019-04-01 | PHASE2; PHASE3 |
| NCT04753112 | COMPLETED | Pulmonary Hypertension |
Germans Trias i Pujol Hospital |
2020-10-29 | PHASE3 |
| NCT04623866 | UNKNOWN | Henoch Schönlein Purpura Nephritis |
The Children's Hospital of Zhejiang University School of Medicine |
2020-11-01 | EARLY_PHASE1 |
| NCT04859452 | COMPLETED | Healthy Subjects |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2021-05-26 | PHASE1 |
| NCT05387967 | COMPLETED | Heart Failure, Systolic |
National Institute of Cardiovascular Diseases, Pakistan |
2021-01-01 | PHASE4 |
| NCT04687111 | UNKNOWN | Atrial Remodeling; Myocardial Dysfunction; Left Ventricular Remodeling; Left Ventricular Diastolic Dysfunction; Hypertension; Cardiovascular Morbidity; Fibrosis Myocardial; Inflammatory Myopathy; Atrial Arrhythmia |
Mark Ledwidge |
2015-12-16 | PHASE2 |
| NCT04800081 | UNKNOWN | Hypertension |
LanZhou University |
2020-07-09 | |
| NCT04335786 | TERMINATED | Acute Respiratory Distress Syndrome; SARS-CoV-2; COVID; COVID-19; Severe Acute Respiratory Syndrome |
Radboud University Medical Center |
2020-04-17 | PHASE4 |
| NCT03917459 | COMPLETED | Heart Failure; Heart Failure, Systolic; Erectile Dysfunction |
Novartis Pharmaceuticals |
2019-04-16 | PHASE3 |
| NCT04688294 | COMPLETED | Heart Failure |
Amir Safwat |
2020-01-01 | PHASE4 |
| NCT04342351 | UNKNOWN | Myocardial Infarction |
RenJi Hospital |
2020-05-01 | PHASE4 |
| NCT03893526 | COMPLETED | Type2 Diabetes |
University of Copenhagen |
2019-01-25 | PHASE4 |
| NCT02924727 | COMPLETED | Acute Myocardial Infarction |
Novartis Pharmaceuticals |
2016-12-09 | PHASE3 |
| NCT03791723 | UNKNOWN | Atrial Fibrillation; Cardiac Remodeling, Atrial; Sacubitril/Valsartan |
The Second Affiliated Hospital of Chongqing Medical University |
2019-06-01 | |
| NCT04458285 | UNKNOWN | Hemodialysis Complication; Heart Failure |
Guangdong Provincial People's Hospital |
2020-01-01 | |
| NCT04575675 | COMPLETED | Hypotension; Heart Failure |
Cheng-Hsin General Hospital |
2020-05-29 | PHASE4 |
| NCT02816736 | COMPLETED | Heart Failure |
Duke University |
2017-03-02 | PHASE4 |
| NCT04206865 | WITHDRAWN | Cardiogenic Shock |
The Cleveland Clinic |
2019-11-25 | PHASE4 |
| NCT03168568 | COMPLETED | Heart Failure |
University of Zurich |
2017-05-04 | PHASE4 |
| NCT04092309 | UNKNOWN | Hematopoietic Stem Cell Transplantation; Cardiotoxicity |
University of Athens |
2019-09-20 | |
| NCT02662894 | WITHDRAWN | Hypertension; Dyslipidemia |
EMS |
2019-10 | PHASE3 |
| NCT03552575 | COMPLETED | Heart Failure |
NHS Greater Glasgow and Clyde |
2018-07-01 | PHASE3 |
| NCT02916160 | COMPLETED | Chronic Heart Failure; Sleep Apnea Syndrome |
University Hospital, Montpellier |
2016-09-22 | PHASE4 |
| NCT04047940 | COMPLETED | Healthy |
Eli Lilly and Company |
2019-11-29 | PHASE1 |
| NCT04128891 | WITHDRAWN | Heart Failure With Preserved Ejection Fraction |
Flinders University |
2020-02-01 | PHASE3 |
| NCT02973035 | COMPLETED | Hypertension |
Asan Medical Center |
2016-12 | PHASE4 |
| NCT03005184 | WITHDRAWN | Heart Failure NYHA Class I; Heart Failure NYHA Class II; Heart Failure NYHA Class III |
Vanderbilt University Medical Center |
2017-09 | PHASE2 |
| NCT03066804 | COMPLETED | Heart Failure With Preserved Ejection Fraction |
Novartis Pharmaceuticals |
2017-08-22 | PHASE3 |
| NCT03432468 | UNKNOWN | Hypertension |
LanZhou University |
2018-04-01 | |
| NCT03119623 | WITHDRAWN | Heart Failure With Reduced Ejection Fraction |
Brigham and Women's Hospital |
2017-06-01 | PHASE4 |
| NCT01912534 | COMPLETED | Hypertrophic Cardiomyopathy |
Carelon Research |
2014-03 | PHASE2 |
| NCT01920711 | COMPLETED | Heart Failure With Preserved Ejection Fraction |
Novartis Pharmaceuticals |
2014-07-18 | PHASE3 |
| NCT03771729 | UNKNOWN | CKD |
The Second Affiliated Hospital of Harbin Medical University |
2018-12-30 | EARLY_PHASE1 |
| NCT02765594 | UNKNOWN | Primary IgA Nephropathy |
Peking Union Medical College Hospital |
2016-06 | PHASE4 |
| NCT03990480 | COMPLETED | Hypertension |
Damanhour University |
2018-12-01 | PHASE4 |
| NCT02754518 | COMPLETED | Heart Failure |
University of Chicago |
2016-04 | PHASE4 |
| NCT01805804 | TERMINATED | First Time Dual Chamber Pacemaker Implantation |
Medical University of Silesia |
2017-01 | PHASE4 |
| NCT04707508 | COMPLETED | Diabetes Mellitus, Type 2 |
Nantou Christian Hospital |
2017-12-01 | PHASE4 |
| NCT02874794 | COMPLETED | Heart Failure and Reduced Ejection Fraction |
Novartis Pharmaceuticals |
2016-08-17 | PHASE4 |
| NCT04085627 | UNKNOWN | Healthy |
Second Affiliated Hospital of Wenzhou Medical University |
2018-10-08 | PHASE1 |
| NCT02788656 | TERMINATED | Congestive Heart Failure |
Brigham and Women's Hospital |
2016-09 | PHASE4 |
| NCT02636283 | TERMINATED | Peripheral Arterial Disease |
University of Minnesota |
2017-12-31 | PHASE2 |
| NCT03279861 | WITHDRAWN | Congestive Heart Failure; Hypertension |
University of Maryland, Baltimore |
2017-11 | PHASE4 |
| NCT02887183 | COMPLETED | Heart Failure |
Novartis Pharmaceuticals |
2016-10-25 | PHASE4 |
| NCT03639480 | UNKNOWN | Hypertension; Hyperlipidemia |
HK inno.N Corporation |
2017-10-13 | PHASE3 |
| NCT03415906 | WITHDRAWN | Heart Failure |
Hannover Medical School |
2017-12-14 | PHASE2 |
| NCT03532854 | COMPLETED | Healthy Male Volunteers |
LG Chem |
2018-05-28 | PHASE1 |
| NCT02554890 | COMPLETED | Acute Heart Failure |
Novartis Pharmaceuticals |
2016-04-29 | PHASE4 |
| NCT02900378 | COMPLETED | Chronic Heart Failure With Reduced Ejection Fraction |
Novartis Pharmaceuticals |
2016-12-20 | PHASE3 |
| NCT02970669 | COMPLETED | Heart Failure, Reduced Ejection Fraction |
Novartis Pharmaceuticals |
2016-12-16 | PHASE4 |
| NCT03180593 | COMPLETED | Hypertension Complicated; Hypertrophy, Left Ventricular; Blood Pressure |
Trinity Hypertension & Metabolic Research Institute |
2017-02-07 | PHASE4 |
| NCT02687932 | COMPLETED | Mitral Valve Insufficiency; Left Ventricular Dysfunction |
Asan Medical Center |
2016-03 | PHASE4 |
| NCT02787798 | TERMINATED | Heart Failure |
University Hospital, Toulouse |
2016-10 | PHASE4 |
| NCT02480764 | COMPLETED | Essential Hypertension |
Takeda |
2015-08-27 | PHASE3 |
| NCT03536598 | COMPLETED | Hypertension With Hyperlipidemia |
HK inno.N Corporation |
2016-10-14 | PHASE3 |
| NCT02690974 | COMPLETED | Hearth Failure With Reduced Ejection Fraction (HFrEF) |
Novartis Pharmaceuticals |
2016-03-08 | PHASE4 |
| NCT02639637 | COMPLETED | Type 2 Diabetes Mellitus |
Vanderbilt University |
2015-12 | PHASE4 |
| NCT04107220 | UNKNOWN | Heart Failure |
Unity Health Toronto |
2016-06 | |
| NCT00655330 | UNKNOWN | Type 2 Diabetes Mellitus; Nephropathy |
Guangdong Provincial People's Hospital |
2008-05 | |
| NCT02572960 | COMPLETED | Osteoporosis; Vitamin D Deficiency; Cardiovascular Disease |
University of Aarhus |
2015-10 | PHASE4 |
| NCT02495324 | COMPLETED | Essential,Hypertension |
Boryung Pharmaceutical Co., Ltd |
2015-06 | PHASE4 |
| NCT01904981 | COMPLETED | Small Abdominal Aortic Aneurysm |
Yonsei University |
2014-01 | PHASE4 |
| NCT01617681 | COMPLETED | Pediatric Hypertension With or Without CKD |
Novartis Pharmaceuticals |
2012-11-08 | PHASE3 |
| NCT03012763 | COMPLETED | Pharmacokinetics; Magnetic Resonance Imaging; Administration, Oral |
University Medicine Greifswald |
2016-04 | PHASE1 |
| NCT03657472 | COMPLETED | Hypertension; Hyperlipidemia |
HK inno.N Corporation |
2016-09-19 | PHASE1 |
| NCT02631031 | COMPLETED | Healthy Normotensive Volunteers |
Ain Shams University |
2015-11 | PHASE1 |
| NCT02433119 | COMPLETED | Hypertension |
Dong-A ST Co., Ltd. |
2015-03-16 | PHASE4 |
| NCT02606279 | TERMINATED | HIV; Aging; Sarcopenia; Angiotensin Receptor Antagonists |
Wake Forest University Health Sciences |
2014-07 | |
| NCT02817217 | UNKNOWN | Type 2 Diabetes |
Jiangsu HengRui Medicine Co., Ltd. |
2016-03 | PHASE1 |
| NCT00503152 | COMPLETED | Diabetes |
Mario Negri Institute for Pharmacological Research |
2007-05 | PHASE3 |
| NCT02145104 | COMPLETED | Hypertension |
IlDong Pharmaceutical Co Ltd |
2014-06-17 | PHASE3 |
| NCT00494715 | COMPLETED | Diabetes |
Mario Negri Institute for Pharmacological Research |
2007-05 | PHASE3 |
| NCT02299310 | UNKNOWN | Chronic Kidney Disease |
Chinese PLA General Hospital |
2014-11 | PHASE4 |
| NCT02062645 | COMPLETED | Essential Hypertension |
Novartis Pharmaceuticals |
2014-02 | PHASE4 |
| NCT01365481 | COMPLETED | Hypertension; Chronic Kidney Disease |
Novartis Pharmaceuticals |
2011-08 | PHASE3 |
| NCT01699490 | UNKNOWN | Major Depressive Disorder |
National Cheng-Kung University Hospital |
2012-08 | PHASE4 |
| NCT03393377 | COMPLETED | Atherosclerosis |
University Medical Centre Ljubljana |
2014-09 | |
| NCT01870739 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2013-10 | PHASE2 |
| NCT00878969 | TERMINATED | Oxidative Stress; Endothelial Dysfunction |
Vanderbilt University |
2010-01 | PHASE3 |
| NCT02403349 | UNKNOWN | Blood Pressure; Ischemic Stroke |
Ajou University School of Medicine |
2012-05 | PHASE4 |
| NCT00140790 | TERMINATED | Hypertension |
Kumamoto University |
2006-08 | PHASE4 |
| NCT01850160 | COMPLETED | Hypertension |
Farma de Colombia SA |
2013-04 | PHASE3 |
| NCT02343250 | COMPLETED | Hypertension |
IlDong Pharmaceutical Co Ltd |
2015-03 | PHASE1 |
| NCT01340326 | COMPLETED | Myocardial Infarction |
Dong-A University |
2007-11 | PHASE4 |
| NCT01819220 | COMPLETED | Hypertension |
Yonsei University |
2009-04 | PHASE4 |
| NCT00721773 | COMPLETED | Renal Function Disorder |
Sun Yat-sen University |
2008-09 | |
| NCT05170061 | COMPLETED | Hypertension |
State University of New York at Buffalo |
2013-02 | PHASE3 |
| NCT02088008 | UNKNOWN | Healthy Volunteers |
IlDong Pharmaceutical Co Ltd |
2014-05 | PHASE1 |
| NCT02058823 | TERMINATED | Hypoxia; Sleep Apnea; Obstructive Sleep Apnea |
University Hospital, Grenoble |
2013-08-07 | PHASE4 |
| NCT02058446 | COMPLETED | Essential Hypertension |
TSH Biopharm Corporation Limited |
2013-10 | PHASE4 |
| NCT02069821 | COMPLETED | Healthy |
HK inno.N Corporation |
2014-03 | PHASE1 |
| NCT02197494 | COMPLETED | Healthy |
Ranbaxy Laboratories Limited |
2014-01 | |
| NCT01878201 | COMPLETED | Essential Hypertension |
Boryung Pharmaceutical Co., Ltd |
2013-05 | PHASE2 |
| NCT02197442 | COMPLETED | Healthy |
Ranbaxy Laboratories Limited |
2014-01 | |
| NCT02815657 | COMPLETED | Type 2 Diabetes |
Jiangsu HengRui Medicine Co., Ltd. |
2013-04 | PHASE1 |
| NCT03309618 | COMPLETED | Myocardial Infarction |
University Medical Centre Ljubljana |
2012-11 | |
| NCT01681576 | COMPLETED | Salt-sensitive Hypertension |
Novartis Pharmaceuticals |
2012-08 | PHASE2 |
| NCT02518451 | COMPLETED | Healthy |
Dexa Medica Group |
2013-06 | |
| NCT01609959 | COMPLETED | Hypertension |
Nara Medical University |
2012-06 | PHASE4 |
| NCT01917149 | COMPLETED | Dilated Cardiomyopathy |
Xijing Hospital |
2005-03 | PHASE4 |
| NCT01318395 | COMPLETED | Arterial Hypertension |
University of Erlangen-Nürnberg Medical School |
2010-05 | PHASE3 |
| NCT01838967 | COMPLETED | Healthy |
IlDong Pharmaceutical Co Ltd |
2013-04 | PHASE1 |
| NCT01928628 | COMPLETED | Hypertension |
LG Life Sciences |
2012-05 | PHASE3 |
| NCT01764178 | COMPLETED | Hyperlipidemia; Hypertension |
JW Pharmaceutical |
2013-01-22 | PHASE1 |
| NCT01508026 | COMPLETED | Stage 1 Hypertension; Stage 2 Hypertension |
Forest Laboratories |
2012-01 | PHASE3 |
| NCT01918332 | COMPLETED | Hypertension,; Hyperlipidemia |
LG Life Sciences |
2012-04 | PHASE3 |
| NCT01672476 | COMPLETED | Hypertension |
Boryung Pharmaceutical Co., Ltd |
2012-04 | PHASE3 |
| NCT01541189 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2012-02 | PHASE4 |
| NCT00426348 | COMPLETED | Glomerulonephritis; IGA Nephropathy |
Guangdong Provincial People's Hospital |
2007-05 | PHASE4 |
| NCT01918358 | COMPLETED | Hypertension; Hyperlipidemia |
LG Life Sciences |
2012-12 | PHASE1 |
| NCT01415505 | COMPLETED | Hypertension |
Forest Laboratories |
2011-08 | PHASE3 |
| NCT01767259 | COMPLETED | Healthy Normotensive Participants |
Damanhour University |
2012-10 | |
| NCT01432106 | WITHDRAWN | Hypertension; Metabolic Syndrome |
University of Michigan |
2011-02 | PHASE1 |
| NCT01767298 | COMPLETED | Healthy Normotensive Participants |
Damanhour University |
2012-10 | |
| NCT01252238 | TERMINATED | Insulin Sensitivity; Aortic Compliance; Diastolic Function |
Brigham and Women's Hospital |
2010-06 | |
| NCT01735890 | COMPLETED | Healthy |
HK inno.N Corporation |
2012-09 | PHASE1 |
| NCT01353508 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2011-03 | PHASE2 |
| NCT01402843 | COMPLETED | Hypertension; Dyslipidemia |
JW Pharmaceutical |
2011-06 | PHASE3 |
| NCT01609907 | COMPLETED | Hypertension; Hyperlipidemia |
Yuhan Corporation |
2011-11 | PHASE1 |
| NCT01494727 | COMPLETED | Healthy |
HK inno.N Corporation |
2012-02 | PHASE1 |
| NCT01004237 | COMPLETED | Hypertension; High Cholesterol |
Gachon University Gil Medical Center |
2009-11 | PHASE4 |
| NCT01030458 | COMPLETED | Blood Pressure |
KU Leuven |
2010-09 | PHASE4 |
| NCT01071122 | COMPLETED | Hypertension |
Bayer |
2010-01 | PHASE4 |
| NCT01129557 | TERMINATED | Proteinuric Kidney Disease; Diabetic Nephropathy; Hypertensive Nephrosclerosis; IgA Nephropathy; Focal Segmental Glomerulosclerosis; Glomerulopathy (Obesity-associated); Glomerulonephritis, Membranous |
Columbia University |
2009-09 | PHASE4 |
| NCT00887588 | COMPLETED | Chronic Heart Failure |
Novartis Pharmaceuticals |
2009-11 | PHASE2 |
| NCT00732069 | COMPLETED | End Stage Renal Failure on Dialysis; Complication of Hemodialysis |
Vanderbilt University |
2008-08 | PHASE2 |
| NCT00858299 | UNKNOWN | Chronic Kidney Disease; Proteinuria |
Samsung Medical Center |
2009-03 | PHASE4 |
| NCT01281306 | COMPLETED | Systolic Hypertension |
Novartis Pharmaceuticals |
2011-01 | PHASE2 |
| NCT01918709 | COMPLETED | Hypertension, Hyperlipidemia |
LG Life Sciences |
2011-09 | PHASE1 |
| NCT01447485 | COMPLETED | Hypertension; Chronic Kidney Disease; Nephrotic Syndrome |
Novartis Pharmaceuticals |
2011-08 | PHASE1 |
| NCT00927394 | COMPLETED | Hypertension |
Novartis |
2009-05 | PHASE4 |
| NCT01406431 | COMPLETED | Hyperlipidemia; Hypertension |
JW Pharmaceutical |
2011-08 | PHASE1 |
| NCT00874601 | UNKNOWN | Acute Ischemic Stroke |
Hallym University Medical Center |
2008-10 | PHASE4 |
| NCT00902304 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2009-07 | PHASE4 |
| NCT00993109 | COMPLETED | Hypertension |
Bayer |
2010-02 | PHASE4 |
| NCT01167153 | COMPLETED | Hypertension |
Novartis |
2010-05 | PHASE4 |
| NCT02519010 | COMPLETED | Healthy |
Genuine Research Center, Egypt |
2011-03 | PHASE1 |
| NCT01232049 | COMPLETED | Healthy |
Asan Medical Center |
2010-10 | PHASE1 |
| NCT01241487 | COMPLETED | Primary Hypertension |
Novartis |
2009-02 | PHASE4 |
| NCT01095822 | UNKNOWN | Diabetes Mellitus |
HeartDrug Research LLC |
2010-03 | PHASE4 |
| NCT00457483 | COMPLETED | Primary Hypertension |
Radboud University Medical Center |
2007-08 | PHASE4 |
| NCT01070043 | COMPLETED | Hypertension; High Blood Pressure |
Novartis |
2009-06 | PHASE4 |
| NCT00162955 | COMPLETED | Non-Hodgkin's Lymphoma |
Osaka City University |
2004-05 | PHASE4 |
| NCT00738972 | TERMINATED | Hypertension |
Fundación Lindavista del Corazón AC |
2008-01 | PHASE3 |
| NCT00129233 | COMPLETED | Hypertension; Type 2 Diabetes Mellitus |
Nagoya University |
2004-10 | PHASE4 |
| NCT01375322 | COMPLETED | Hypertension; Diabetes Mellitus, Type 2; Albuminuria |
TSH Biopharm Corporation Limited |
2007-06 | PHASE4 |
| NCT01122251 | COMPLETED | Essential Hypertension |
LG Life Sciences |
2009-12 | PHASE2 |
| NCT01001572 | COMPLETED | Essential Hypertension |
Novartis |
2009-09 | PHASE3 |
| NCT00657241 | COMPLETED | Hypertension |
State University of New York at Buffalo |
2008-04 | PHASE3 |
| NCT01115972 | COMPLETED | Healthy; Pharmacokinetics of Valsartan |
Astellas Pharma Inc |
2010-03 | PHASE1 |
| NCT00446563 | COMPLETED | Hypertension; Hypertrophy, Left Ventricular |
Novartis |
2007-03 | PHASE3 |
| NCT00500604 | COMPLETED | Hypertension |
Sanofi |
2007-07 | PHASE4 |
| NCT00931710 | COMPLETED | Stage 2 Systolic Hypertension |
Novartis |
2009-07 | PHASE4 |
| NCT00589732 | COMPLETED | Coronary Artery Disease |
Seung-Jung Park |
2006-09 | PHASE4 |
| NCT00790946 | UNKNOWN | Hypertension; Obesity |
Kagoshima University |
2006-06 | PHASE4 |
| NCT00939588 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2009-07 | PHASE2 |
| NCT00208767 | COMPLETED | Carotid Artery Diseases; Atherosclerosis |
Emory University |
2005-02 | PHASE2 |
| NCT00550095 | COMPLETED | Microalbuminuria; Proteinuria |
Novartis |
2007-06 | PHASE4 |
| NCT00819767 | COMPLETED | Hypertension |
Novartis |
2009-02 | PHASE2 |
| NCT00097786 | COMPLETED | Diabetes Mellitus, Type 2 |
Novartis Pharmaceuticals |
2002-01 | PHASE3 |
| NCT00518362 | COMPLETED | Diabetic Nephropathy |
Nanjing University School of Medicine |
2007-07 | |
| NCT00591578 | COMPLETED | Hypertension |
Takeda |
2007-12 | PHASE3 |
| NCT00732966 | UNKNOWN | Hypertension |
Assaf-Harofeh Medical Center |
2008-09 | |
| NCT00922441 | COMPLETED | Essential Hypertension |
Boryung Pharmaceutical Co., Ltd |
2008-12 | PHASE2 |
| NCT00745953 | WITHDRAWN | Metabolic Syndrome; Lipotoxicity |
University of Texas Southwestern Medical Center |
2007-08 | PHASE4 |
| NCT00696436 | COMPLETED | Hypertension |
Takeda |
2008-04 | PHASE3 |
| NCT00661895 | COMPLETED | Hypertension |
Creighton University |
2005-08 | PHASE4 |
| NCT00809926 | COMPLETED | Stage 2 Hypertension |
Novartis |
2009-01 | PHASE4 |
| NCT00698646 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2008-04 | PHASE4 |
| NCT00446511 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2007-06 | PHASE3 |
| NCT00457626 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2007-04-09 | PHASE3 |
| NCT00921570 | COMPLETED | Diabetes; Hypertension; Proteinuria |
Gulhane School of Medicine |
2008-02 | PHASE4 |
| NCT00699192 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2008-05 | PHASE3 |
| NCT00546754 | COMPLETED | Hypertension |
Organon and Co |
2007-05-01 | PHASE3 |
| NCT00295542 | COMPLETED | Hypertension |
University of Vigo |
2000-03 | PHASE4 |
| NCT00409578 | COMPLETED | Post Acute Coronary Syndrome; Myocardial Ischemia |
Novartis |
2007-02 | PHASE2 |
| NCT00839683 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-02 | PHASE1 |
| NCT00518219 | COMPLETED | Membranous Nephropathy |
Nanjing University School of Medicine |
2007-07 | PHASE4 |
| NCT00433836 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2007-01 | PHASE3 |
| NCT01400256 | WITHDRAWN | Stroke, Acute |
Stanford University |
2007-08 | PHASE4 |
| NCT00716950 | UNKNOWN | Essential Hypertension |
University of Pavia |
2008-07 | PHASE4 |
| NCT00687973 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2008-01 | PHASE4 |
| NCT00149227 | COMPLETED | Hypertension; Ischemic Heart Disease; Congestive Heart Failure; Stroke |
Kyoto Prefectural University of Medicine |
2004-01 | PHASE4 |
| NCT00391846 | COMPLETED | Heart Failure; Ventricular Dysfunction, Left |
AstraZeneca |
2006-10 | PHASE4 |
| NCT00435162 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2007-03 | PHASE3 |
| NCT00666536 | COMPLETED | Hypertension |
Novartis |
2008-03 | PHASE4 |
| NCT00460213 | COMPLETED | Hypertension |
Kitakyushu-Tsuyazaki Hospital |
2006-07 | PHASE4 |
| NCT00424801 | TERMINATED | Microvascular Angina; Hypertension |
University of Aarhus |
2007-01 | |
| NCT01425411 | COMPLETED | Hypertension; Left Ventricular Hypertrophy |
Mustafa Kemal University |
2006-11 | PHASE4 |
| NCT00446524 | COMPLETED | Hypertension |
Novartis |
2007-02 | PHASE3 |
| NCT00130156 | COMPLETED | High Blood Pressure |
Eisai Inc. |
2005-10 | PHASE4 |
| NCT00700271 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2007-10 | PHASE4 |
| NCT00386607 | COMPLETED | Hypertension |
Novartis |
2006-10 | PHASE3 |
| NCT00599885 | COMPLETED | Hypertension; Diabetes; Coronary Artery Disease |
Korea University Anam Hospital |
2007-09 | PHASE4 |
| NCT00549770 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2007-09 | PHASE2 |
| NCT00309257 | COMPLETED | Alport Syndrome |
Mario Negri Institute for Pharmacological Research |
2004-01 | PHASE2 |
| NCT00687206 | COMPLETED | Hypertension; Ventricular Remodeling; Erectile Dysfunctions |
Federico II University |
2008-03 | PHASE4 |
| NCT00190580 | COMPLETED | Chronic Kidney Disease; Hypertension |
KVT-Study Group |
2003-02 | PHASE4 |
| NCT00151229 | COMPLETED | Aged; Systolic Hypertension |
VALISH study |
2003-10 | PHASE4 |
| NCT00425373 | COMPLETED | Essential Hypertension |
Novartis Pharmaceuticals |
2006-11 | PHASE2; PHASE3 |
| NCT00523549 | COMPLETED | Hypertension; Diastolic Dysfunction |
Novartis Pharmaceuticals |
2006-11 | PHASE4 |
| NCT00376272 | COMPLETED | Atrial Fibrillation |
Gruppo di Ricerca GISSI |
2004-11 | PHASE3 |
| NCT00523744 | COMPLETED | Hypertension |
Novartis |
2007-07 | PHASE3 |
| NCT00396656 | COMPLETED | Hypertension |
Novartis |
2005-12 | PHASE3 |
| NCT00437645 | COMPLETED | Essential Hypertension |
Novartis Pharmaceuticals |
2007-01 | PHASE3 |
| NCT00413049 | COMPLETED | Hypertension |
Novartis |
2007-01 | PHASE3 |
| NCT00400777 | COMPLETED | Hypertension |
Novartis |
2006-08 | PHASE4 |
| NCT00439738 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2006-12 | PHASE4 |
| NCT00413413 | COMPLETED | Hypertension |
Novartis Pharmaceuticals |
2007-01 | PHASE3 |
| NCT00171054 | COMPLETED | Hypertension |
Novartis |
2003-09 | PHASE4 |
| NCT00425997 | COMPLETED | Hypertension |
Novartis |
2006-12 | PHASE4 |
| NCT00487123 | COMPLETED | Hypertension |
Novartis |
PHASE4 | |
| NCT00338936 | COMPLETED | Hypertension |
Novartis |
2006-05 | PHASE3 |
| NCT00171132 | COMPLETED | Hypertension |
Novartis |
2004-08 | PHASE4 |
| NCT00327587 | COMPLETED | Hypertension |
Novartis |
2006-05 | PHASE3 |
| NCT00171106 | COMPLETED | Diastolic Dysfunction, Symptomatic Heart Failure |
Novartis |
2002-12 | PHASE4 |
| NCT00394745 | COMPLETED | Hypertension; Metabolic Syndrome |
Novartis |
2005-11 | PHASE3 |
| NCT00394823 | COMPLETED | Hypertension |
Novartis |
2005-11 | PHASE3 |
| NCT00171067 | COMPLETED | Hypertension |
Novartis |
2004-07 | PHASE3 |
| NCT00219102 | COMPLETED | Hypertension; Diabetes |
Novartis |
2005-06 | PHASE3 |
| NCT00350168 | COMPLETED | Hypertension |
Novartis |
2006-06 | PHASE3 |
| NCT00353912 | COMPLETED | Hypertension |
Novartis |
2006-06 | PHASE3 |
| NCT00310778 | COMPLETED | Healthy |
Assistance Publique - Hôpitaux de Paris |
2006-03 | PHASE1 |
| NCT00351130 | COMPLETED | Hypertension |
Novartis |
2006-06 | PHASE4 |
| NCT00200694 | TERMINATED | Heavy Proteinuria |
Nantes University Hospital |
2005-03 | PHASE4 |
| NCT00821574 | COMPLETED | Hypertension, Dyslypidaemia |
Novartis |
2005-07 | PHASE4 |
| NCT00302705 | COMPLETED | Hypertension |
University of Vigo |
2005-01 | PHASE4 |
| NCT00392262 | COMPLETED | Hypertension |
Novartis |
2006-08 | PHASE3 |
| NCT00304226 | COMPLETED | Hypertension |
Novartis |
2006-02 | PHASE4 |
| NCT00219193 | COMPLETED | Hypertension |
Novartis |
2005-10 | PHASE3 |
| NCT00294086 | COMPLETED | Chronic Heart Failure |
Novartis |
2005-12 | PHASE2 |
| NCT00171600 | TERMINATED | Hypertension; Early Diabetic Nephropathy |
Novartis |
2005-07 | PHASE4 |
| NCT00327145 | COMPLETED | Hypertension |
Novartis |
2006-03 | PHASE3 |
| NCT00360178 | COMPLETED | Hypertension |
Novartis |
2006-07 | PHASE3 |
| NCT00409487 | COMPLETED | Hypertension,; Obstructive Sleep Apnea |
University Hospital, Grenoble |
2006-12 | PHASE4 |
| NCT00171028 | COMPLETED | Hypertension |
Novartis |
2003-12 | PHASE3 |
| NCT00982358 | COMPLETED | Hypertension; Type 2 Diabetes Mellitus; Coronary Artery Disease |
Charite University, Berlin, Germany |
2004-07 | PHASE4 |
| NCT00171561 | COMPLETED | Hypertension |
Novartis |
2003-03 | PHASE4 |
| NCT00311740 | COMPLETED | Hypertension |
Novartis |
2006-03 | PHASE3 |
| NCT00254475 | COMPLETED | Essential Hypertension; Hypercholesterolemia |
Novartis |
2005-11 | PHASE3 |
| NCT00219180 | COMPLETED | Hypertension |
Novartis |
2005-06 | PHASE3 |
| NCT00280540 | COMPLETED | Hypertension |
Novartis |
2005-12 | PHASE4 |
| NCT00171574 | COMPLETED | Hypertension; Diabetic Nephropathy |
Novartis |
2004-11 | PHASE4 |
| NCT00273299 | COMPLETED | Hypertension |
Novartis |
2005-11 | PHASE3 |
| NCT00168779 | COMPLETED | Hypertension |
Boehringer Ingelheim |
2005-09 | PHASE4 |
| NCT00367939 | COMPLETED | Hypertension |
Novartis |
2005-12 | PHASE3 |
| NCT00250562 | COMPLETED | Hypertension |
Novartis |
2005-10 | PHASE3 |
| NCT00170924 | COMPLETED | Diastolic Dysfunction; Hypertension |
Novartis |
2004-08 | PHASE4 |
| NCT00170937 | COMPLETED | METABOLIC SYNDROME; HYPERTENSION; PRE-HYPERTENSION |
Novartis |
2004-11 | PHASE4 |
| NCT00171756 | COMPLETED | Hypertension |
Novartis |
2004-06 | PHASE4 |
| NCT00171041 | COMPLETED | Hypertension |
Novartis |
2002-12 | PHASE3 |
| NCT00171080 | COMPLETED | Hypertension |
Novartis |
2004-04 | PHASE3 |
| NCT00171093 | COMPLETED | HYPERTENSION; HYPERCHOLESTEROLEMIA |
Novartis |
2004-09 | PHASE3 |
| NCT00153023 | COMPLETED | Diabetic Nephropathies; Hypertension |
Boehringer Ingelheim |
2003-04 | PHASE4 |
| NCT00277472 | COMPLETED | Hypertension |
Novartis |
2005-11 | PHASE4 |
| NCT00171353 | COMPLETED | Hypertension |
Novartis |
2004-07 | PHASE4 |
| NCT00171327 | COMPLETED | Hypertension; Dyslipidemia |
Novartis |
2004-07 | PHASE4 |
| NCT00241085 | COMPLETED | PROTEINURIA; Hypertension; Type 2 Diabetes |
Novartis |
2002-11 | PHASE4 |
| NCT00170989 | COMPLETED | Hypertension |
Novartis |
2004-09 | PHASE3 |
| NCT00241072 | COMPLETED | Hypertension; Impaired Glucose Tolerance |
Novartis |
2002-09 | PHASE4 |
| NCT00154271 | COMPLETED | Hypertension |
Novartis |
2004-01 | PHASE4 |
| NCT00170963 | COMPLETED | Hypertension |
Novartis |
2004-10 | PHASE3 |
| NCT00241124 | COMPLETED | Hypertension |
Novartis |
2004-04 | PHASE4 |
| NCT00308425 | COMPLETED | De Novo Renal Transplantation |
Novartis |
2002-10 | PHASE3 |
| NCT00170976 | COMPLETED | HYPERTENSION |
Novartis |
2004-04 | PHASE3 |
| NCT00171002 | COMPLETED | Hypertension |
Novartis |
2004-11 | PHASE3 |
| NCT00241098 | COMPLETED | Hypertension; Congestive Heart Failure |
Novartis |
2003-05 | PHASE4 |
| NCT00171444 | COMPLETED | Hypertension |
Novartis |
2004-06 | PHASE4 |
| NCT00333489 | COMPLETED | Hypertension |
Novartis |
2004-03 | PHASE4 |
| NCT00171535 | COMPLETED | Hypertension |
Novartis |
2004-10 | PHASE3 |
| NCT00171015 | COMPLETED | Hypertension |
Novartis |
2004-12 | PHASE3 |
| NCT00241007 | COMPLETED | Hypertension |
Novartis |
2003-12 | PHASE3 |
| NCT00409851 | COMPLETED | Hypertension |
Novartis |
2003-04 | PHASE3 |
| NCT00171119 | TERMINATED | Hypertension; Diabetic Nephropathy |
Novartis Pharmaceuticals |
2004-01 | PHASE4 |
| NCT00241150 | COMPLETED | Hypertension; Metabolic Syndrome |
Novartis |
2002-11 | PHASE4 |
| NCT00241137 | COMPLETED | Hypertension |
Novartis |
2003-09 | PHASE3 |
| NCT00239538 | COMPLETED | Hypertension; Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2003-01 | PHASE4 |
| NCT00171782 | COMPLETED | HYPERTENSION |
Novartis |
2004-02 | PHASE4 |
| NCT00409643 | COMPLETED | Hypertension |
Novartis |
2004-01 | PHASE3 |
| NCT00240448 | COMPLETED | Hypertension |
Boehringer Ingelheim |
2003-09 | PHASE4 |
| NCT00409760 | COMPLETED | Hypertension |
Novartis |
2003-01 | PHASE3 |
| NCT06395194 | COMPLETED | Essential Hypertension |
Oslo University Hospital |
1997-09-27 | PHASE3 |
| NCT00385931 | COMPLETED | Hypertension; Hypercholesterolemia; Dyslipidemia |
Novartis |
2002-01 | PHASE3 |
| NCT02242318 | COMPLETED | Hypertension |
Boehringer Ingelheim |
2001-09 | PHASE4 |
| NCT00034840 | COMPLETED | Hypertension |
Boehringer Ingelheim |
2001-10 | PHASE4 |
| NCT02177396 | COMPLETED | Hypertension |
Boehringer Ingelheim |
1998-04 | PHASE3 |
| NCT00530595 | COMPLETED | Cardiovascular Disease |
Saitama Medical University |
||
| NCT00202618 | UNKNOWN | Hypertension; Diabetes Mellitus; Albuminuria |
Shiga University |
2003-12 | PHASE4 |
| NCT00426478 | COMPLETED | Hypertension |
Novartis |
2006-11 | PHASE4 |
| NCT00089518 | WITHDRAWN | HIV Infections; Kidney Disease |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00416468 | COMPLETED | Healthy |
Novartis |
2006-11 | PHASE1 |
| NCT00518479 | COMPLETED | Hypertension; Left Ventricular Hypertrophy |
University of Leeds |
2003-09 | |
| NCT00416728 | COMPLETED | Healthy |
Novartis |
2006-11 | PHASE1 |
| NCT00133328 | UNKNOWN | Hypertension; Ischemic Heart Disease; Congestive Heart Failure |
Jikei University School of Medicine |
2002-01 | PHASE4 |
| NCT00415883 | COMPLETED | Healthy |
Novartis |
2006-07 | PHASE1 |
| NCT00627991 | WITHDRAWN | Cerebrovascular Accident |
Stanford University |
2007-08 | |
| NCT00185055 | COMPLETED | Healthy |
Daiichi Sankyo |
2004-11 | PHASE4 |
| NCT00407680 | UNKNOWN | Type 2 Diabetes Mellitus; Hypertension |
Kitasato University |
2006-10 | PHASE4 |
| NCT00343499 | TERMINATED | Atrial Fibrillation |
Intermountain Health Care, Inc. |
2004-11 | PHASE4 |
| NCT00548067 | COMPLETED | Hypertension |
Novartis |
2007-09 | PHASE3 |
| NCT00367562 | COMPLETED | IGA Nephropathy |
Hospital Britanico |
1996-01 | PHASE4 |
(data from https://clinicaltrials.gov, updated on 2026-01-22)
Check the
Valsartan
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.